Recordati signs Ionis licensing deal for zilganersen outside US, pays $30 million upfront

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONS

0.00
  • Recordati signed a license deal with Ionis for exclusive rights to develop and commercialize zilganersen outside the U.S. for Alexander disease.
  • Recordati will handle regulatory filings and commercialization ex-U.S., including country-level early-access support; Ionis keeps U.S. commercialization.
  • Ionis will receive an upfront payment of USD 30 million.
  • Ionis is eligible for additional milestone payments and tiered royalties up to the mid-20% range on annual net sales.
  • Zilganersen showed positive pivotal-study data, meeting the primary endpoint with 50 mg stabilizing gait speed versus control at Week 61.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.